Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
Voir aussi
Avis et décisions de la HAS
17/11/2017
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
dMqe8QknSUg2GM1p
Écouter
